-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Follicular Lymphoma Drug Details: Sovleplenib (HMPL-523) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Sovleplenib (HMPL-523)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Marginal Zone B-cell Lymphoma Drug Details: Sovleplenib (HMPL-523)...
-
Thematic Analysis
NewMobile Gaming – Thematic Intelligence
Mobile Gaming Thematic Intelligence Report Overview The mobile gaming market is already bigger than the console and PC gaming markets combined. The growing maturity of streaming (supported by 5G), cloud gaming, and mobile esports, combined with the fact that mobile platforms are close to technological parity with PCs and consoles, means most gamers will embrace mobile gaming in the next few years. The mobile gaming thematic intelligence report provides an overview of the mobile gaming theme and identifies the key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Momelotinib Dihydrochloride in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Momelotinib Dihydrochloride in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Momelotinib Dihydrochloride in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Small-Cell Lung Cancer Drug Details: Surufatinib (Sulanda) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...